These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy. Heymann MA; Clyman RI Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200 [TBL] [Abstract][Full Text] [Related]
3. Prostaglandins and the management of congenital heart disease. Taylor WJ; Alpert BS Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758 [TBL] [Abstract][Full Text] [Related]
4. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease. Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664 [TBL] [Abstract][Full Text] [Related]
5. The ductus arteriosus: why and how to manipulate its patency. Drummond WH; Bucciarelli RL; Gessner IH J Fla Med Assoc; 1983 Sep; 70(9):788-93. PubMed ID: 6355376 [No Abstract] [Full Text] [Related]
7. Prostaglandin E1 in infants with congenital heart disease: Indian experience. Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540 [TBL] [Abstract][Full Text] [Related]
8. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects. Park IS; Nihill MR; Titus JL J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824 [No Abstract] [Full Text] [Related]
9. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant. Strauss A; Modanlou HD; Gyepes M; Wittner R Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810 [TBL] [Abstract][Full Text] [Related]
10. Use of prostaglandins in duct-dependent congenital heart conditions. Singh Y; Mikrou P Arch Dis Child Educ Pract Ed; 2018 Jun; 103(3):137-140. PubMed ID: 29162633 [TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects. Reddy SC; Saxena A Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966 [TBL] [Abstract][Full Text] [Related]
13. [Skeletal side effects of treatment with prostaglandin E1]. Persigehl M; Hövels-Gürich H; von Bernuth G Rofo; 1984 Oct; 141(4):427-30. PubMed ID: 6436918 [TBL] [Abstract][Full Text] [Related]
14. Nursing care of the neonate receiving prostaglandin E1 therapy. Rikard DH Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622 [TBL] [Abstract][Full Text] [Related]
15. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1]. Fujii S; Nagai I; Yonei A; Sari A; Baba K Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818 [No Abstract] [Full Text] [Related]
19. Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation. Huang FK; Lin CC; Huang TC; Weng KP; Liu PY; Chen YY; Wang HP; Ger LP; Hsieh KS Pediatr Neonatol; 2013 Apr; 54(2):102-6. PubMed ID: 23590954 [TBL] [Abstract][Full Text] [Related]
20. Use of prostaglandins in cardiopulmonary diseases of the newborn. Olley PM; Coceani F Semin Perinatol; 1980 Apr; 4(2):135-41. PubMed ID: 6990504 [No Abstract] [Full Text] [Related] [Next] [New Search]